High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
View Patent ↗Granules of racemic sodium ibuprofen dihydrate formed from components specified herein have very desirable properties and can be effectively used in conventional rotary press tableting equipment without operational difficulties often encountered in actual practice. Their preparation by a wet granulation process, the wet granule compositions, formulations adapted for preparation of solid dosage forms utilizing a rotary press, solid dosage forms, and methods of preparing solid dosage forms in a rotary press are also described.
1. A highly dispersible, flee-flowing granule composition
having a high content of sodium ibuprofen dihydrate, which composition is formed from components in powder form, said components comprising (i) 80 to 98 parts by weight of sodium ibuprofen dihydrate on a dry basis, (ii) 1 to 4 parts by weight of anhydrous sodium carbonate on a dry basis, and (iii) 1 to 10 parts by weight of non-crosslinked polyvinylpyrrolidone on a dry basis, wherein said granule composition is prepared by a method which comprises:
bringing together in a high shear granulator components comprised of (i) 80-90 parts by weight on a dry basis of sodium ibuprofen dihydrate, (ii) 1 to 4 parts by weight on a dry basis of anhydrous sodium carbonate, (iii) 1 to 10 parts by weight on a dry basis of non-crosslinked polyvinylpyrrolidone, and (iv) 8 to 12 parts by weight of water based on the total weight of (i), (ii), (iii), and (iv) to form a wet mixture;
granulating said wet mixture in said high shear granulator to form wet granules;
drying wet granules to form dried granules having a moisture content in the range of about 12.5 to 15 wt % as determinable by measurement of weight loss at 110° C.; and
removing by sieving dried granules having a particle size greater than 16 mesh wherein the granule composition does not form punch coating when being subjected to a tablet-forming process.
2. A granule composition as in claim 1 , wherein said composition is formed from components comprising (i) about 95 parts by weight of sodium ibuprofen dihydrate on a dry basis, (ii) about 2 to 3 parts by weight of anhydrous sodium carbonate on a dry basis, and (iii) about 2 to 3 parts by weight of non-crosslinked polyvinylpyrrolidone on a dry basis.
3. A granule composition as in claim 1 wherein said dried granule exhibits during differential scanning calorimetry a phase transition peaking in the range of about 100° C. to about 102° C., and wherein the size of the DSC peak, which peak corresponds to solids-to-solids phase transition, is at least about 150 joules per gram.
4. A granule composition as in claim 1 wherein said granules have a moisture content in the range of about 11 to about 15 wt %, as determinable by measurement of weight loss at 110° C.
5. A wet granule composition having a high content of sodium ibuprofen dihydrate, which composition is formed from components in powder form, said components comprising (i) sodium ibuprofen dihydrate in an amount of 80-90 wt % on a dry basis, (ii) anhydrous sodium carbonate in an amount in the range of 1 to 4 wt % on a dry basis, (iii) non-crosslinked polyvinylpyrrolidone in an amount in the range of 1 to 10 wt % on a dry basis, and (iv) water in an amount in the range of 8 to 12 wt % based on the total weight of (i), (ii), (iii), and (iv), wherein the wet granule composition does not form punch coating when being subjected to a tablet-forming process.
6. A wet granule composition as in claim 5 wherein said composition is formed from components comprising (i) sodium ibuprofen dihydrate in an amount of about 95 wt % on a dry basis, (ii) anhydrous sodium carbonate in an amount of about 2 to 3 wt % on a dry basis, (iii) non-crosslinked polyvinylpyrrolidone in an amount of about 3 to 2 parts by weight on a dry basis, and (iv) water in an amount in the range of about 8 to 12 wt % based on the total weight of (i), (ii), (iii), and (iv).
7. A sodium ibuprofen dihydrate formulation adapted for preparation of solid dosage forms using a rotary press, which formulation is formed from components which comprise:
1.40 to about 100 wt % of a granule composition as in claim 1 ;
0 to about 25 wt % of microcrystalline cellulose, calcium hydrogen phosphate, or both;
0 to about 8 wt % of crospovidone or sodium croscarmellose;
0 to about 0.5 wt % of colloidal silica;
0 to about 10 wt % starch; and
0 to about 2 wt % stearic acid, magnesium stearate, or both, wherein said granule composition is prepared by a method which comprises:
bringing together in a high shear granulator components comprised of (i) 80-90 parts by weight on a dry basis of sodium ibuprofen dihydrate, (ii) 1 to 4 parts by weight on a dry basis of sodium carbonate, (iii) 1 to 10 parts by weight on a dry basis of non-crosslinked polyvinylpyrrolidone, and (iv) 8 to 12 parts by weight of water based on the total weight of (i), (ii), (iii), and (iv) to form a wet mixture;
granulating said wet mixture in said high shear granulator to form wet granules;
drying wet granules to form dried granules having a moisture content in the range of about 12.5 to 15 wt % as determinable by measurement of weight loss at 110° C.; and
removing by sieving dried granules having a particle size greater than 16 mesh, wherein the formulation does not form punch coating when being subjected to a tablet-forming process using the rotary press.
8. A formulation as in claim 7 wherein the amount of the granule composition is in the range of about 70 to about 100 wt %, the amount of microcrystalline cellulose is 0 to about 20 wt %, and the amount of crospovidone or sodium croscarmellose is 0 to about 8 wt %, and the amount of colloidal silica is 0 to about 0.2 wt %.
9. A formulation as in claim 7 wherein the amount of the granule composition is in the range of about 90 to about 100 wt %, the amount of microcrystalline cellulose is 0 to about 10 wt %, and the amount of crospovidone or sodium croscarmellose is 0 to about 6 wt %, and the amount of colloidal silica is 0 to about 0.2 wt %.
10. A formulation as in claim 7 wherein the amount of the granule composition is in the range of about 60 to about 90 wt %, the amount of microcrystalline cellulose, calcium hydrogen phosphate dihydrate, or both, is about 10 to about 30 wt %, the amount of crospovidone or sodium croscarmellose is 0 to about 6 wt %, the amount of starch is 0 to about 6 wt %, the amount of stearic acid, magnesium stearate, or both, is 0 to about 2 wt %, and the amount of colloidal silica is 0 to about 0.25 wt %.
11. A formulation as in claim 7 wherein the amount of the granule composition is in the range of about 85 to about 100 wt %, the amount of microcrystalline cellulose, calcium hydrogen phosphate dihydrate, or both, is 0 to about 10 wt %, the amount of starch is 0 to about 6%, the amount of crospovidone or sodium croscarmellose is 0 to about 5 wt %, the amount of colloidal silica is 0 to about 0.25 wt %, and the amount of stearic acid, magnesium stearate, or both, is 0 to about 2 wt %.
12. A solid dosage form formed from a formulation as in claim 7 .
13. A dosage form which comprises a hard-shell capsule containing a granule composition as in claim 1 .
14. A method of preparing solid dosage forms of sodium ibuprofen dihydrate, which method comprises compressing in a rotary press a granule composition as in claim 1 .